| Literature DB >> 25111170 |
Jean-Baptiste Ronat1, Jabar Kakol2, Marwan N Khoury3, Mathilde Berthelot1, Oliver Yun1, Vincent Brown1, Richard A Murphy4.
Abstract
OBJECTIVE: In low- and middle-income countries, bloodstream infections are an important cause of mortality in patients with burns. Increasingly implicated in burn-associated infections are highly drug-resistant pathogens with limited treatment options. We describe the epidemiology of bloodstream infections in patients with burns in a humanitarian surgery project in Iraq.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25111170 PMCID: PMC4128596 DOI: 10.1371/journal.pone.0101017
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Map of Iraq showing area of Sulaymaniyah.
Patient demographics and type of injury.
| Demographic/Type | N (%) |
| Gender | 1,169 |
| Male | 374 (32) |
| Female | 795 (68) |
| Age | |
| 0–5 | 362 (31) |
| 6–14 | 141 (12) |
| 15–29 | 362 (31) |
| 30–59 | 257 (22) |
| ≥60 | 47 (4) |
| Mechanism of injury | |
| Fire/flame | 421 (36) |
| Scalding | 631 (54) |
| Contact | 82 (7) |
| Other | 35 (3) |
| Place of injury | |
| Home (including yard) | 970 (83) |
| Work | 129 (11) |
| School/outdoors | 70 (6) |
| Alleged intent of injury | |
| Accidental, self | 946 (81) |
| Accidental, other | 129 (11) |
| Intentional, self | 82 (7) |
| Intentional, other | 12 (1) |
| % TBSA burned (median 18%, IQR 9.5–39.0) | |
| ≤15 | 338 (29) |
| 15–30 | 468 (40) |
| 31–50 | 234 (20) |
| 51–69 | 82 (7) |
| ≥70 | 47 (4) |
| Hours between injury and presentation (median, IQR) | 1, (0.5–1.5) |
TBSA, total body surface area.
Patient care outcomes and mortality.
| Outcome | N (%) |
| N = 1169 | |
| Length of hospital stay: median 8 days, IQR 3–14 | |
| Admission outcome | |
| Recovery | 772 (66) |
| Death | 303 (26) |
| Discharged against medical advice | 94 (8) |
| Cause of death | |
| Inhalation injury | 106 (35) |
| Sepsis | 198 (65) |
| Mortality by % TBSA burned | |
| ≤15 | 0 (n/a) |
| 15–30 | 70 (15% died) |
| 31–50 | 119 (51% died) |
| 51–69 | 78 (95% died) |
| ≥70 | 47 (100% died) |
| Proven bacteremia (n = 65) by % TBSA burned (median 59%, IQR 36.5–77.0) | |
| ≤15 | 0 (n/a) |
| 15–30 | 11 (18% sepsis) |
| 31–50 | 20 (30% sepsis) |
| 51–69 | 34 (52% sepsis) |
| ≥70 | 0 (n/a) |
TBSA, total body surface area.
General bacteria etiology among blood culture isolates.
| Organism | N = 65 | |
| n | % | |
| Gram-negative bacteria | 41 | 63 |
| Gram-positive bacteria | 24 | 37 |
| Specific organisms identified | ||
|
| 22 | 33 |
|
| 17 | 26 |
|
| 8 | 12 |
|
| 9 | 14 |
|
| 7 | 11 |
|
| 5 | 8 |
Resistance profile for gram-negative bacteria.
| Organisms |
|
|
|
|
| N = 8 | N = 5 | N = 22 | N = 6 | |
| n (%R) | n (%R) | n (%R) | n (%R) | |
| Ampicillin/Sulbactam | 1 (17) | |||
| Amoxicillin/Clavulanic ac | 4 (50) | |||
| Ticarcillin/Clavulanic ac | 8 (100) | 5 (100) | 16 (73) | 5 (83) |
| Piperacillin | 5 (100) | 14 (64) | 6 (100) | |
| Piperacillin/Tazobactam | 7 (87) | 2 (40) | 9 (41) | 4 (67) |
| Cephalothin (CIG) | 8 (100) | |||
| Cefuroxime (CIIG) | 8 (100) | 5 (100) | ||
| Ceftazidime (CIIIG) | 7 (87) | 5 (100) | 12 (54) | 4 (67) |
| Cefepime (CIVG) | 4 (50) | 4 (80) | 7 (32) | 3 (50) |
| Gentamicin | 8 (100) | 4 (80) | 21 (95) | 6 (100) |
| Amikacin | 6 (75) | 1 (20) | 5 (23) | 4 (67) |
| Ciprofloxacin | 5 (62) | 1 (20) | 14 (64) | 3 (50) |
| Co-trimoxazole | 4 (50) | 4 (80) | ||
| Imipenem | 0 (0) | 0 (0) | 5 (23) | 2 (33) |
| Colistin | 0 (0) | 0 (0) |
Proportion of blood culture isolates that were multidrug-resistant.
| Organism | Multidrug-resistant isolates | |
| n/N | % | |
| Gram-negative bacteria | 26/41 | 63 |
| Gram-positive bacteria | 22/24 | 92 |
| Specific organisms identified | ||
|
| 14/22 | 64 |
|
| 17/17 | 100 |
|
| 4/8 | 50 |
|
| 4/9 | 67 |
|
| 5/7 | 71 |
|
| 4/5 | 80 |
|
|
|
|
Resistance profile of Gram-positive bacteria.
| Organism |
|
|
| N = 17 | N = 7 | |
| n (%R) | n (%R) | |
| Penicillin G | 17 (100) | 7 (100) |
| Oxacillin | 17 (100) | 5 (71) |
| Gentamicin | 15 (88) | 2 (29) |
| Fusidic acid | 12 (71) | 3 (43) |
| Levofloxacin | 10 (59) | 1 (14) |
| Clindamycin | 6 (35) | 0 (0) |
| Minocycline | 5 (29) | 1 (14) |
| Rifampin | 5 (29) | 0 (0) |
| Quinupristin/Dalfopristin | 2 (12) | 0 (0) |
| Nitrofurantoin | 0 (0) | 0 (0) |
| Vancomycin | 0 (0) | 0 (0) |